SciClone Pharmaceuticals (SciClone Pharmaceuticals) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2017)

SciClone Pharmaceuticals Cash-to-Debt Chart

SciClone Pharmaceuticals Annual Data
	Trend	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16
Cash-to-Debt		Get a 7-Day Free Trial					58.29	52.02	No Debt	No Debt	No Debt

SciClone Pharmaceuticals Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of SciClone Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals's Cash-to-Debt falls into.

SciClone Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

SciClone Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

SciClone Pharmaceuticals had no debt ⁽¹⁾.

SciClone Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2017 is calculated as:

SciClone Pharmaceuticals had no debt ⁽¹⁾.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SciClone Pharmaceuticals  (NAS:SCLN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

SciClone Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description